Clinical trials: Cancer of the Head and Neck
Metastatic Esophageal Adenocarcinoma, Metastatic Esophageal Squamous Cell Carcinoma
Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
This randomized phase II trial studies how well paclitaxel with or without cixutumumab works in treating patients with esophageal cancer or gastroesophageal junction cancer that has spread to other places in the body…
- Conditions
- Metastatic Esophageal Adenocarcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Recurrent Esophageal Adenocarcinoma
- Trial name
- NCT01142388
- Testing
- Cixutumumab, Laboratory Biomarker Analysis, Paclitaxel
- Where
- 232 sites in United States
- Volunteers
- 94 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Cancer
Tislelizumab Combined With Chemotherapy or Radiotherapy in the Treatment of Advanced or Recurrent Metastatic Elderly Esophageal Cancer
To compare the objective response rate (ORR) and safety of tislelizumab combined with chemotherapy and Tislelizumab combined with radiotherapy in elderly patients with esophageal cancer with advanced or recurrent metastasis
- Trial name
- NCT05628610
- Testing
- Tislelizumab, Radiation, Paclitaxel
- Volunteers
- 130 people
- Sponsor
- Fujian Cancer Hospital
Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
A Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Neck Cancer
This Phase 2, open-label, multicenter study will evaluate the safety and preliminary efficacy of axelopran in combination with pembrolizumab in patients with PD-L1 positive recurrent or metastatic head and neck squamous cell…
- Trial name
- MORALE-HN01 (NCT07662720)
- Testing
- axelopran, Pembolizumab
- Volunteers
- 18 people
- Sponsor
- Glycyx Therapeutics
Head and Neck Cancer
Study Evaluating Near-infrared Imaging Coupled With Indocyanine Green for Intraoperative Control of Resection Margins in ENT Surgery
Assess the sensitivity of real-time near-infrared fluorescence imaging to detect microscopic residual disease in the operating room after a complete macroscopic surgical resection of head and neck cancers
- Trial name
- MAGNOLIA (NCT04842162)
- Testing
- indocyanine green
- Where
- 2 sites in Belgium, France
- Volunteers
- 65 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Squamous Cell Carcinoma
Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma
The primary hypothesis of this study is that the addition of mammalian target of rapamycin (mTOR) blockade to conventional epidermal growth factor receptor (EGFR) blockade will result in synergistic clinical activity in Squamous…
- Trial name
- NCT01009203
- Testing
- Erlotinib, Temsirolimus
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- New Mexico Cancer Research Alliance
Malignant Head and Neck Neoplasm
ProvoxLife Adoption Trends for Heat-Moisture Exchanger
This study examines factors that affect how often patients who have a total laryngectomy use a ProvoxLife heat-moisture exchanger (HME) system to help improve their lung function.
- Trial name
- NCT05036330
- Testing
- Clinical Evaluation, Physical Examination, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- M.D. Anderson Cancer Center
Adenocarcinoma of the Gastroesophageal Junction, Cervical Cancer
Validation of a Nutrition Screening Tool
The objective of this study is to evaluate the sensitivity and specificity of two nutrition screening tools to identify inpatients with malnutrition or at risk of malnutrition.
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Cervical Cancer, Endometrial Cancer, Esophageal Cancer
- Trial name
- NCT01851928
- Where
- United Kingdom
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Royal Marsden NHS Foundation Trust
Head and Neck Cancer
Cetuximab Therapeutic Drug Monitoring in Squamous Cell Carcinoma Head and Neck Cancer Patients: Determination of the Predictive Value Exposure Levels Through a Single Arm Multicentric Study
Only about 30 percent of cancer patients have a clinical benefit upon cetuximab administration. Pilot studies in colorectal and head and neck cancer patients have suggested that cetuximab pharmacokinetics (PK), i.e.
- Trial name
- CETUXIMAX (NCT04218136)
- Testing
- Blood samples
- Where
- France
- Volunteers
- 122 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Head and Neck Cancer
A Prospective Study of Daily Adaptive Radiotherapy to Better Organ-at-Risk Doses in Head and Neck Cancer
Varian Medical Systems has recently deployed a completely novel radiation treatment system called EthosTM, a first-of-its-kind system that allows for daily adapative radiotherapy (DART), such that the treatment for that day can…
- Trial name
- DARTBOARD (NCT04883281)
- Testing
- Intensity modulated radiation therapy (IMRT) with or without chemotherapy, cisplatin, cetuximab, or carboplatin-paclitaxel
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Texas Southwestern Medical Center
Head and Neck Cancer
Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN
This research study is studying immunotherapy in combination with radiation therapy as a possible treatment for head \& neck cancer that has worsened or spread to another organ or part of your body.
- Trial name
- NCT03085719
- Testing
- Pembrolizumab, Radiation
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Dana-Farber Cancer Institute
Neoplasms
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
The purpose of this study is to evaluate if the combination of GSK3359609 and tremelimumab is safe and tolerable (Part 1) and provides significant survival benefit to subjects with relapsed/refractory (R/R) Head and Neck Squamous…
- Trial name
- NCT03693612
- Testing
- feladilimab, Tremelimumab, Docetaxel
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 26 people
- Sponsor
- GlaxoSmithKline
Head and Neck Cancer, Oropharyngeal Cancer
Robotic Assisted Surgery in Upper Aerodigestive Tract Surgery
To evaluate the use of the daVinci Robotic System for better visibility and access of head and neck lesions and decreased amount of surgery time.
- Conditions
- Head and Neck Cancer, Oropharyngeal Cancer, Hypopharyngeal Cancer, Upper Aerodigestive Tract Neoplasms
- Trial name
- NCT00473564
- Testing
- da Vinci® Robotic System
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- University of Alabama at Birmingham
Drug/Agent Toxicity by Tissue/Organ, Head and Neck Cancer
Chemotherapy Plus Radiation Therapy With or Without Amifostine in Treating Patients With Locally Advanced Cancer of the Nasopharynx
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Head and Neck Cancer, Oral Complications, Radiation Toxicity
- Trial name
- NCT00025298
- Testing
- amifostine trihydrate, carboplatin, cisplatin
- Where
- 13 sites in Belgium, France and 4 more
- Volunteers
- 5 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Head and Neck Cancer
Central Pain Syndrome in Survivors of Head and Neck Cancer
This is a cross-sectional pilot study of head and neck cancer survivors who have completed multi-modal treatment to assess and characterize the presence of distinct pain syndromes.
- Trial name
- NCT04128267
- Testing
- IPC-1000, Magnetic resonance imaging, Correlative Studies
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Vanderbilt-Ingram Cancer Center
Cancer Head Neck, Metastatic Cancer
Non-invasive Measurement of PD-L1 Levels With Positron Emission Tomography (PET) in Head and Neck Malignancies and Intracranial Metastases
This study aims to determine the feasibility of non-invasive quantitative PD-L1 measurement using [a novel PD-L1 positron emission tomography (PET) tracer and perform immunohistochemistry based measurement of PD-L1 levels within…
- Conditions
- Cancer Head Neck, Metastatic Cancer, Metastatic Lung Cancer
- Trial name
- NCT05408871
- Testing
- adnectin 18F-BMS-986192 Head and Neck Cancer, adnectin 18F-BMS-986192 Brain Metastases
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Yale University
Urinary Bladder Cancer, Melanoma
MAGE-A4ᶜ¹º³²T for Multi-Tumor
This study will investigate the safety and tolerability of MAGE-A4ᶜ¹º³²T cell therapy in subjects who have the appropriate HLA-A2 tissue marker and whose urinary bladder, melanoma, head and neck, ovarian, non-small cell lung…
- Conditions
- Urinary Bladder Cancer, Melanoma, Head and Neck Cancer, Ovarian Cancer
- Trial name
- NCT03132922
- Testing
- Autologous genetically modified MAGE-A4ᶜ¹º³²T cells, Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation
- Where
- 11 sites in United States, Canada
- Volunteers
- 71 people
- Sponsor
- USWM CT, LLC
Tongue Cancer
Radiotherapy of Tongue Cancer Using an Intraoral Stent
Radiotherapy of tongue cancer is associated with acute and late morbidity. Use of an intraoral stent will provide a larger distance between the tongue and palate and can reduce side-effects.
- Trial name
- NCT04337853
- Testing
- Intraoral stent, No intraoral stent
- Where
- Norway
- Volunteers
- 13 people
- Sponsor
- Oslo University Hospital
Cervical Cancer, Fallopian Tube Cancer
Immunotoxin Therapy in Treating Patients With Advanced Cancer
RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be an effective treatment for advanced cancer.
- Conditions
- Cervical Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer
- Trial name
- NCT00006981
- Testing
- SS1(dsFv)-PE38 immunotoxin
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Thyroid Neoplasms, Head and Neck Neoplasms
An Imaging Study in Patients With Thyroid Cancer or Head and Neck Cancer With Pertechnetate Made in a Cyclotron (C-PERT)
Doctors at the Cross Cancer Institute have developed a new method of producing 99mTc Pertechnetate in a cyclotron unit. A study done at the Cross Cancer Institute in 2011 with ten patients using this imaging agent showed that it…
- Trial name
- NCT01747512
- Testing
- C-PERT, G-PERT
- Sponsor
- AHS Cancer Control Alberta
Esophageal Cancer Stage III
The Effect of Neoadjuvant Chemoimmnotherapy Combined With Node Sparing Radiotherapy for cT3N+ EC
Background The promising therapeutic outcomes of neoadjuvant chemoimmnotherapy in the treatment of locally advanced esophageal squamous cell carcinoma (ESCC) have been confirmed by several phase II clinical trials and have been…
- Trial name
- NCT06965829
- Testing
- Tislelizumab, Carboplatin and Paclitaxel and Radiation Therapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Chest Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.